inflammation and an altered microbiota. The immune system is a critical regulator of the braingut axis. Toll-like receptors (TLRs) are pattern recognition molecules regulating innate immunity.
The aim of this study was to characterize TLR activity in IBS.
Methods: Thirty IBS patients and 30 healthy controls (HC) were recruited. Venous blood was collected, and cultured with a panel of TLR agonists for 24 hours. Cell supernatants were analysed using a multiplex ELISA approach to measure IL1β, IL6, IL8 and TNFα. Plasma was analysed for levels of inflammatory cytokines and cortisol.
Results: TLR agonist-induced cytokine (IL1β, IL6, IL8 and TNFα) release was markedly enhanced in stimulated whole blood from IBS (n=30) patients compared with healthy controls (n=30). An exaggerated response to the TLR8 agonist for all cytokines investigated was seen in IBS patients. In addition, enhanced TLR2-induced TNFα release, TLR3-induced IL-8 release, TLR4-induced IL1β and TNFα release, TLR5-induced IL1β and TNFα release and TLR7-induced IL-8 release were also observed in IBS patients. No differences in TLR1, TLR6 or TLR9 activity were detected. In addition, plasma levels of cortisol, IL-6 and IL-8 were significantly increased in IBS patients.
Conclusion:
Taken together, these data demonstrate elevated cytokine levels and TLR activity in the periphery of IBS patients indicating some immune dysregulation in IBS patients.
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Enzyme-linked Immunosorbent Assay (ELISA):
Measurements of IL-1β, IL-6, IL-8 and TNFα in both plasma and following TLR agonist stimulation of whole blood was carried out using an electrochemiluminescence multiplex system with the Mesoscale Discovery (MSD) 4-plex Human Proinflammatory Kit II. Measurements of IL-2, IL-4, IL-5, IL-10, IL-12p70, IL-13, IFN-γ in plasma were carried out in duplicate using the MSD 7-plex Human Th1/Th2 kit. ELISA plates were analysed using the Sector 2400 imager from
Mesoscale Discovery (Gaithersburg, MD, USA). This is an ultra-sensitive method which has a detection limit for IL-1β of 0.3pg/ml, IL-6 of 0.3pg/ml, IL-8 of 1.0pg/ml, IL-10 of 1.9pg/ml, IL12p70 of 1.1pg/ml, IL-13 of 2.8pg/ml, TNFα of 0.3pg/ml, and IFNγ of 0.8pg/ml. Plasma cortisol 
Statistical Analysis:
The sample size was determined by a power calculation based on of our previous data and aimed at detecting differences between IBS patients and healthy controls at the 0.05 level. ELISA data was expressed as mean +/-SEM. All statistical analysis was carried out using GraphPad Prism for Windows (Version 4). Plasma cortisol cytokine levels were compared using an unpaired twotailed Student's t-test, differences were considered significant at P < 0.05. Differences between the IBS and control groups for TLR-agonist induced release of cytokines were determined using two-way ANOVA with a Bonferroni post-hoc test. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Demographic data for IBS patients and control subjects are presented on Table 1 . There were no significant differences between the groups in terms of age, gender distribution or body mass index (BMI). According to Rome II subclassification in terms of predominant bowel habit, this cohort had 11 alternating (IBS-A), 10 constipation-predominant (IBS-C) and 9 diarrhoea-predominant (IBS-D) patients. IBS symptoms were assessed using the IBS-SS, it was found that the average cumulative score for the IBS patients was 258.8 (moderate) compared to 4.83 (out of 500) for the control subjects; as expected, the difference was highly significant (p < 0.0001) (Table 1) .
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Additionally, 2 of the control group had a family history of IBS compared to 13 of the IBS group (Table 1) .
Plasma cytokine and cortisol levels:
Plasma from both healthy controls and IBS patients was analyzed for eleven cytokines and cortisol. Student's t-tests (with correction for multiple comparisons) confirmed that there were significantly elevated levels of IL-6 (p = 0.008), IL-8 (p = 0.028) and cortisol (p = 0.048) in the plasma of IBS patients compared to healthy controls (Figure 1) . Levels of other cytokines tested (IL-1β, TNFα, IL-2, IL-4, IL5, IL-10, IL-12, IL-13 and IFNγ) were not found to be significantly different between groups (Table 2) . No sex differences were found for plasma cortisol or cytokines measured.
TLR-agonist cytokine release:
Supernatants from whole blood treatments with TLR agonists of both healthy controls and IBS patients were analysed for levels of four different pro-inflammatory cytokines IL-1β, IL-6, IL-8 was entered as a co-variate the differences between the groups are still significant.
Post-hoc analysis of individual treatments revealed significant differences between IBS patients and healthy controls. In the untreated blood, levels of IL8 were found to be 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w 9 85.61 pg/ml; p < 0.01) following treatment with the TLR5 agonist Flagellin (Figure 3a) . No significant differences were found following treatment with the TLR6/1 agonist FSL1 ( Figure   3b ). IL-8 release was found to be significantly elevated in IBS compared to HC blood (3408 +/-112.2 vs. 2128 +/-147.9 pg/ml; p < 0.001) following treatment with the TLR7 agonist Imiquimod (Figure 3c ). IL-1β release was found to be significantly elevated following treatment with the TLR8 agonist ssRNA40 (1404 +/-118.5 vs. 913.8 +/-88.15 pg/ml; p < 0.001), IL6 release was found to be significantly elevated (2037 +/-144.3 vs. 1326 +/-137.6 pg/ml; p < 0.01); in addition IL-8 release was found to be significantly elevated (3438 +/-126.9 vs. 2477 +/-146.8 pg/ml; p < 0.001); finally, TNFα release was found to be significantly elevated in IBS compared to HC blood following treatment with the ssRNA40 (1944 +/-161.2 vs. 1076 +/-110.3 pg/ml; p < 0.001) (Figure 3d ). No significant changes in cytokine levels were detected following treatment with the TLR9 agonist ODN2006 (Figure 3e) . A separate analysis was carried out of male and female participants. There was no significant difference between these groups with the exception of LPS (TLR4) induced cytokine release, where there was significantly more IL1β, IL6 and TNFα released in female IBS compared to male IBS patients (Data not shown). and IL-8 were significantly elevated in IBS patients, in agreement with previous studies 11, 30 .
The effects of elevated cytokine levels on the pathophysiology of IBS remain to be release. IL-8 release was greater following activation with agonists for TLR3, 7 and 8. All of these receptors recognise viral nucleic acids. Finally, increased TNFα release was related to increased TLR2, 4, 5 and 8 activities. Enhanced TLR8-mediated cytokine release was the common factor in relation to each of these cytokines. At present, viral nucleic acids are the only known ligand for TLR8 17 , although a yet undiscovered endogenous or exogenous ligand(s) may also activate this receptor. In addition, there were some differences between male and female patients for LPS stimulation, indicating changes in TLR4 activity may be linked not only to the condition but also sex, and further studies are needed to investigate this matter.
IBS patients have been shown to have a different microbiota to that of healthy controls 37 . The gut microbiota are known to have an influence on a number of physiological parameters including the immune system and may prime immune cells that enter the peripheral circulation 38 . This may impact on the TLR expression profile of immune cells and result in altered TLR activity. Indeed, our group has recently reported increased expression of TLR4 in mucosal biopsies from IBS patients 23 . Secondly, IBS patients appear to be particularly susceptible to stress 11 and this seems to have effect on gut motility 9, 10 . It is apparent from both animal models and clinical studies that chronic stress may affect the immune response 31 .
Repeated social defeat stress in mice enhanced the bactericidal activity of splenic macrophages, and led to an increase in the expression of TLR2 and TLR4 on these cells 39 . Social defeat can also activate splenic dendritic cells and enhance TLR activity on these cells as assessed by cytokine output in response to ligand stimulation 40 . Furthermore, chronic restraint stress resulted in immune suppression which was mediated by TLR4 41, 42 . Elevations in the expression of TLR mRNA was observed in the colonic mucosa of two different rat models of stress-induced visceral hypersensitivity when compared to normosensitive rats 22 . These rats develop visceral hypersensitivity, changes in immune response and differences in the gut microbial populations 43 . Thirdly, cytokines and glucocorticoids may synergise to alter TLR expression 44, 45 . Plasma cytokines and cortisol have been shown to be elevated in this cohort of patients and this potentially may explain why there are increases in TLR activity in these patients.
A limitation of the current study is that the TLR receptor activity in the periphery may not resemble that of the gut mucosa. This study has provided novel insights into relationships between TLR activation, plasma cytokine levels and clinical phenotype among a well characterised group of IBS patients. We have described for the very first time, distinctive patterns of TLR activity in the periphery. Based on observed relationships between certain phenotypic features and demonstrated associations between stress and TLR expression and activity in animal models, it is plausible to suggest that there maybe a link between stress, TLR activation and cytokine profiles in IBS patients. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Shown is a comparison of demographic data collected on the study's cohort of healthy controls and IBS patients. Data was collected from medical and family history questionnaires while additional information was taken from specific questionnaires regarding IBS severity (IBS-SS).
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Data is expressed as mean +/-SEM. Student's t-test was used to determine significant differences (p-values shown).
Table 2:
Shown is a table of cytokine and cortisol levels in the plasma of healthy controls and IBS patients.
Data is expresses as mean +/-SEM. Student's t-test was used to determine significant differences.
Figure 1:
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